End-to-end diagnostic services for biopharma partners, including biomarker discovery, assay design and development, fit-for-purpose regulatory strategies, clinical trial testing, commercialization, and companion diagnostic capabilities.
Identify the right patient for the right drug at the right time with our breadth of biomarker discovery and assay development services. Our proven multi-omic expertise, which includes genomic and proteomic assay development and leverages our proprietary AI platform, increases therapeutic success and accelerates drug development for biopharma partners.
Confidently navigate the clinical trial process for novel therapeutics, with proven solutions, including kit design/distribution, sample management, data analytics, data management, quality and regulatory services.
Strategic companion diagnostic services arm biopharma partners with superior diagnostic solutions to overcome the challenges and risks associated with drug discovery, development and commercialization.
Our core belief is that no single technology will answer all diagnostic research questions that we encounter. We employ a blood-based, multiple technology approach for diagnostic research to uncover novel insights about the tumor biology and patient’s immune response to cancer for biopharmaceutical therapeutics in clinical development. Our services support known target feasibility studies as well as unbiased diagnostic research to discover novel biomarkers of interest.
We are experts at profiling the patient's immune response to their cancer with blood-based proteomic solutions in addition to traditional genomic insights. Our technologies and machine learning expertise allow us to identify clinically relevant proteomic differences in patient populations to help guide treatment strategy
We use highly-sensitive technologies to provide comprehensive genomic diagnostic insights.
We have significant experience working with customers from over 50 companies across the biopharmaceutical industry, and a growing sample and data biobank of over 150,000. Our services drive near- and long-term value, as well as ongoing revenue for our partners, which have included Pfizer, Genentech, AstraZeneca, Merck, HiberCell and more.